B
Baker Bros. Advisors LP
+ HoldingRVMD
+18.95%
3M Return
$207.880
-12.473 (-6.00%)At close
Loading chart…
- High
- 221.500
- Open
- 221.500
- VWAP
- 211.73
- Vol
- 2.01M
- Mkt Cap
- 6.36B
- Low
- 205.820
- Amount
- 424.84M
- EV/EBITDA, TTM
- 0.00
Revolution Medicines, Inc. is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The Company's research and development pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The Company is advancing a pipeline of RAS(ON) Inhibitors, daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor are in clinical development. The Company's pipeline also focus on RAS(ON) mutant-selective inhibitors, including RMC-0708 (Q61H) and RMC-8839 (G13C). The Daraxonrasib, our RAS(ON) multi-selective inhibitor, is designed as an oral, tri-complex inhibitor of multiple RAS(ON) variants containing cancer driver mutations at all three of the major RAS mutation hotspot positions, G12, G13, and Q61.
AI analysis of Revolution Medicines Inc (RVMD)
buyRevolution Medicines Inc is a good buy right now due to the recent FDA approval of its drug Rasonque, which is projected to generate $28 million in sales this quarter and has a long-term sales potential of $11.5 billion. Additionally, the stock has seen a remarkable year-to-date change of +163.07% and is currently priced at $207.88, with analysts raising price targets significantly, indicating strong future upside.
Valuation Metrics
The current forward P/E ratio for Revolution Medicines Inc (RVMD) is 0.00, compared to its 5-year average forward P/E of -8.44.
Whales holding RVMD
Events Timeline
News
9.008-28FoolRevolution Medicines Secures FDA Approval for Rasonque
8.508-28NASDAQ.COMRevolution Medicines' Rasonque Gains FDA Approval, Huge Potential Ahead
8.508-27stocktwitsRevolution Medicines' Rasonque Approved, Target Raised to $251
9.008-26stocktwitsSELLAS Life Sciences' SLS009 Slows Pancreatic Cancer Cells
9.008-26stocktwitsRevolution Medicines' Rasonque Approved as First Commercial Drug
RVMD FAQ — answered by Alphio AI
Revolution Medicines, Inc. is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The Company's research and development pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The Company is advancing a pipeline of RAS(ON) Inhibitors, daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor are in clinical development. The Company's pipeline also focus on RAS(ON) mutant-selective inhibitors, including RMC-0708 (Q61H) and RMC-8839 (G13C). The Daraxonrasib, our RAS(ON) multi-selective inhibitor, is designed as an oral, tri-complex inhibitor of multiple RAS(ON) variants containing cancer driver mutations at all three of the major RAS mutation hotspot positions, G12, G13, and Q61. It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry).
Revolution Medicines Inc is a good buy right now due to the recent FDA approval of its drug Rasonque, which is projected to generate $28 million in sales this quarter and has a long-term sales potential of $11.5 billion. Additionally, the stock has seen a remarkable year-to-date change of +163.07% and is currently priced at $207.88, with analysts raising price targets significantly, indicating strong future upside.
Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.